Loading
Latest filing published 16 Apr 2026 for 미래에셋생명.
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
박성철 (chief executive) discloses dealings in 2 companies, chiefly 미래에셋생명 and 큐리옥스바이오시스템즈. In total, 3 filings cover trades dated from 6 March 2026 to 10 April 2026.
The open-market record is one-sided, with 3 purchases worth €196k and not one sale. The amount is not disclosed for 1 filing. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
On 3 out of 3 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.
Most recently, on 16 April 2026, the filings show an open-market purchase in 미래에셋생명. Typically, a trade is published a median of 6 days after it takes place. Until a filing is published, the market cannot know about the trade. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations